First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

This is a Phase I, first-in-human study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic adenocarcinoma (PDAC).

Trial Details

NCT ID
NCT04665947
Phase
EARLY_PHASE1
Sponsor
University of California, Davis
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Locations (sample)
  • Sacramento, California, United States|38.58157,-121.4944

Key Eligibility Criteria

  • \[68Ga\]Ga DOTA-5G PET/CT Inclusion Criteria:
  • Ability to understand and willingness to sign a written informed consent document.
  • Age 18 or more years
  • Confirmed presence of locally advanced, unresectable or metastatic pancreatic adenocarcinoma (other pancreatic malignant histologies are excluded) …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →